TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed Price. Currency in USD
12.91
+0.59 (+4.79%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close12.32
Open12.49
Bid0.00 x 29200
Ask13.00 x 800
Day's range12.09 - 12.92
52-week range6.07 - 13.76
Volume15,894,775
Avg. volume17,965,612
Market cap14.231B
Beta (5Y monthly)1.60
PE ratio (TTM)N/A
EPS (TTM)-0.76
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date27 Nov 2017
1y target est10.89
  • Got $3,000? These 5 Beaten-Down Stocks Are Begging to Be Bought
    Motley Fool

    Got $3,000? These 5 Beaten-Down Stocks Are Begging to Be Bought

    No matter how dire things may have appeared in previous bear markets, bull-market rallies eventually erase all evidence of downward moves in the stock market. Also keep in mind that you don't have to be rich to generate a handsome return from the stock market. With the exception of the oil and gas industry, there's probably not a harder-hit industry lately than bank stocks.

  • Business Wire

    Teva Announces Virtual 2020 Annual Meeting of Shareholders

    Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) ("Teva"), announced today that, in the interest of the health and safety of its shareholders, directors, officers and employees in light of the current COVID-19 pandemic, the format of its 2020 Annual Meeting of Shareholders has been changed to a virtual meeting. Teva’s 2020 Annual Meeting will be held on Tuesday, June 9, 2020 at 4:30 p.m., Israel time (9:30 a.m., New York time), as previously announced.

  • Business Wire

    Teva Presented New Data at the European Academy of Neurology Congress Evaluating the AJOVY® (fremanezumab) Experience in Populations with Difficult-to-Treat Migraine

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented a wide range of important new data on AJOVY® (fremanezumab) and the societal and economic impact of migraine in Europe at the 6th Congress of the European Academy of Neurology (EAN). This year’s EAN congress was a virtual meeting due to the global coronavirus pandemic.

  • Can Teva (TEVA) Return to Growth in This Year or Next?
    Zacks

    Can Teva (TEVA) Return to Growth in This Year or Next?

    Though Teva (TEVA) faces several challenges, with encouraging progress on restructuring activities and stabilization in the generics business, it may return to growth in 2020 or 2021.

  • Business Wire

    Teva to Present New AJOVY® (fremanezumab) Analyses and Latest COPAXONE® Data (glatiramer acetate injection) at European Academy of Neurology Congress

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on AJOVY® (fremanezumab) and the burden of migraine in Europe will be presented at the 6th Congress of the European Academy of Neurology (EAN), being held virtually from 23-26 May 2020. Additionally, Teva will present data on the long-term safety and efficacy of COPAXONE® (glatiramer acetate injection). This year’s EAN congress is a virtual meeting due to the global coronavirus pandemic. All Teva abstracts will be published in a supplement to the European Journal of Neurology.

  • 3 Absolutely No-Brainer Bear Market Buys
    Motley Fool

    3 Absolutely No-Brainer Bear Market Buys

    Beginning in late February, we witnessed the broad-based S&P 500 endure the fastest descent into bear market territory in history -- it took a little over three weeks. Every bear market correction in history has proved to be an excellent buying opportunity for long-term-minded investors. This means that if you buy businesses with game-changing potential at a discount during a bear market, you'll be setting yourself up to make a lot of money.

  • Business Wire

    China Approves AUSTEDO® For Treating Chorea Associated with Huntington's Disease and Tardive Dyskinesia in Adults

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the China National Medical Products Administration (NMPA) has approved AUSTEDO® (Deutetrabenazine Tablets) for the treatment of chorea associated with Huntington's disease (HD) and Tardive Dyskinesia (TD) in adults, after a priority review. China is the second country in the world after the U.S. to have approved AUSTEDO.

  • Is Teva Pharmaceutical Industries Ltd (TEVA) Stock Undervalued Right Now?
    Zacks

    Is Teva Pharmaceutical Industries Ltd (TEVA) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Teva Pharmaceutical Industries Limited (TEVA) Q1 2020 Earnings Call Transcript
    Motley Fool

    Teva Pharmaceutical Industries Limited (TEVA) Q1 2020 Earnings Call Transcript

    Ladies and gentlemen, thank you for standing by, and welcome to today's Teva Pharmaceutical First Quarter 2020 Financial Results. Delay, I would now like to hand the conference over to presenter today, Kevin Mannix, Senior Vice President and Head of Investor Relations. Thank you, operator, and thank you, everyone, for joining us today to discuss Teva's First Quarter 2020 Financial Results.

  • Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales
    Zacks

    Teva (TEVA) Q1 Earnings Top, Coronavirus-Led Buying Aids Sales

    Teva (TEVA) beats estimates for earnings and sales in first-quarter 2020. It maintains previously issued guidance for 2020. Stock up.

  • Here's Why Teva Pharmaceuticals Jumped Higher Today
    Motley Fool

    Here's Why Teva Pharmaceuticals Jumped Higher Today

    Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are up 11% at 1:50 p.m. EDT after the drugmaker announced first-quarter earnings that beat expectations. For most drugmakers, 5% growth would be a slow quarter, but Teva has been struggling of late, with its multiple sclerosis drug Copaxone facing generic competition and a decline in its U.S. generic business, which resulted in revenue falling 8% year over year -- 5% in local currency terms -- in 2019. On the non-COVID-19 plus side, U.S. sales of Austedo, which treats tardive dyskinesia and Huntington's disease chorea, were up 64% year over year to $122 million.

  • Teva (TEVA) Q1 Earnings & Sales Beat Estimates, Stock Up
    Zacks

    Teva (TEVA) Q1 Earnings & Sales Beat Estimates, Stock Up

    Teva beats estimates for earnings and sales in first-quarter 2020. It maintains its previously issued guidance for 2020. Stock up.

  • Business Wire

    Teva Reports First Quarter 2020 Financial Results

    Teva Pharmaceutical Industries Ltd. (NYSE: TEVA, TASE: TEVA) today reported results for the quarter ended March 31, 2020.

  • Will a Migraine Drug Save This Debt-Ridden Giant?
    Motley Fool

    Will a Migraine Drug Save This Debt-Ridden Giant?

    Teva's sales have been declining on all fronts while it remains mired in opioid litigation. Can a new venture into migraine treatment eliminate its troubles?

  • Corcept Therapeutics Incorporated (CORT) Q1 2020 Earnings Call Transcript
    Motley Fool

    Corcept Therapeutics Incorporated (CORT) Q1 2020 Earnings Call Transcript

    CORT earnings call for the period ending March 31, 2020.

  • Teva (TEVA) to Report Q1 Earnings: What's in the Cards?
    Zacks

    Teva (TEVA) to Report Q1 Earnings: What's in the Cards?

    On Teva's (TEVA) first-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products

  • Business Wire

    Teva and Celltrion Healthcare Announce the Launch of TRUXIMA® (rituximab-abbs) Injection for Rheumatoid Arthritis, the Only Biosimilar to Rituxan® (rituximab) Available in the United States for This Indication

    Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Celltrion Healthcare, Co., Ltd. (KRX KOSDAQ:091990), today announced that TRUXIMA® (rituximab-abbs) injection is now available in the United States for the treatment of:

  • Business Wire

    New Data For Teva AJOVY® (fremanezumab-vfrm) Injection and AUSTEDO® (deutetrabenazine) Tablets Included in Neurology

    Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data for AJOVY® (fremanezumab-vfrm) injection and AUSTEDO® (deutetrabenazine) tablets have appeared in an online supplement to Neurology. The data includes 23 abstracts that highlight a diverse set of data evaluating the efficacy and safety of AJOVY and AUSTEDO.

  • Got $2,000? Park It in These Top Stocks for 10 Years.
    Motley Fool

    Got $2,000? Park It in These Top Stocks for 10 Years.

    The proliferation of the coronavirus disease 2019 (COVID-19) initially sent the benchmark S&P 500 to its fastest bear market in history (17 trading sessions), as well as the quickest descent to a 30% loss from recent highs on record (22 trading session). More recently, we've witnessed a whipsaw rally in the broad-based S&P 500 that's approaching 30%. While this is probably not how investors envisioned beginning the new decade, it's actually one heck of an opportunity for those with cash to spare.

  • Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
    Zacks

    Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know

    In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $10.84, marking a +1.12% move from the previous day.

  • Business Wire

    Teva Announces U.S. Launch of Autoinjector for AJOVY® (fremanezumab-vfrm) Injection

    Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the autoinjector device for AJOVY® (fremanezumab-vfrm) injection is now available in the U.S. AJOVY is indicated for the preventive treatment of migraine in adults and is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine treatment with quarterly (675 mg) and monthly (225 mg) subcutaneous dosing options.

  • Business Wire

    Teva to Host Conference Call to Discuss First Quarter 2020 Financial Results at 8 a.m. ET on May 7, 2020

    Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its first quarter financial results on Thursday, May 7, 2020 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

  • Teva Canada Committed to Canadian Caregivers
    CNW Group

    Teva Canada Committed to Canadian Caregivers

    On National Caregiver Day, Teva Canada acknowledges all caregivers and the critical work they provide in supporting our healthcare system both in times of crisis and normalcy, and remains committed to providing the most relevant information and resources to help caregivers feel confident in the care they provide through caregiver-focused programs. Today, in Canada , there are eight million caregivers that play an important role in advocating, mediating and coordinating care with health care professionals, but they need more support. According to Statistics Canada's General Social Survey 2018 (released January 2020 ), almost a quarter struggle to understand the treatment program and condition of the person they are caring for; 56 per cent look for information specific to the medical condition of the care recipient and 36 per cent require help or advice from medical professionals.

  • U.S. court rules for Teva in migraine patent dispute with Eli Lilly
    Reuters

    U.S. court rules for Teva in migraine patent dispute with Eli Lilly

    Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that could help it fend off competition from Eli Lilly and Co in the market for migraine drugs. The Patent Trial and Appeal Board (PTAB) upheld the validity of three Teva patents on its migraine treatment Ajovy, rejecting arguments by Eli Lilly that they were invalid. In a separate legal action filed in 2018, Teva accused Eli Lilly's competing drug Emgality of infringing the same patents.

  • The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
    Zacks

    The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie

    The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie